Synaptic levels refer to the amount of chemical messengers, also known as neurotransmitters, that are present in the synapse, or the gap between two neurons. These levels are regulated by the presynaptic neuron, and their changes can impact the way they respond to stimulus. Neurotransmitters can either excite or inhibit the postsynaptic neuron, causing changes in its electrical activity. Changes in synaptic levels have a wide range of effects that range from changes in behavior to changes in memory and learning. Receptors within the postsynaptic membrane respond to the neurotransmitter released by the presynaptic neuron, and these can be both excitatory or inhibitory. Excitatory receptors are typically glutamate or acetylcholine receptors, and they enhance the neuron’s activity when activated. This can cause the neuron to fire off an action potential, or a nerve impulse. In contrast, inhibitory receptors can dampen the neuron’s activity when activated by a transmitter, such as gamma-aminobutyric acid (GABA). The amount of neurotransmitter released by a presynaptic neuron can be regulated by numerous factors, including electrical or chemical signals. The activity of the presynaptic neuron can be altered by external factors as well, such as food, stress, and exercise. Drugs and alcohol can also affect synaptic levels, as they can increase or decrease the amount of neurotransmitters released. When neurotransmitter levels are too low in the synapse, it can lead to dysfunctional neuron communication. This can lead to a variety of psychiatric and neurological disorders, including depression, anxiety, and Alzheimer’s disease. It can also cause memory loss, coordination problems, and other cognitive deficits. Conversely, changes in synaptic levels can also affect learning and memory. By enhancing communication between neurons, synaptic levels can speed up certain learning processes, such as habit formation.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States